Major clinical studies of systemic chemotherapy in MF/SS
| Therapy . | Study type . | Efficacy . | Durability . |
|---|---|---|---|
| EPOCH | NR14 | ORR stage IIB-IV: 80% | PFS: 8 mo |
| CHOP-based | NR15 | ORR stage IIB: 66% | |
| Fludarabine plus α-interferon | NR16 | ORR stage IIA-IVA: 58% | PFS: 5.9 mo |
| ORR stage IVB: 40% | |||
| Fludarabine plus cyclophosphamide | NR17 | ORR stage IIB-III: 55% | DOR: 10 mo |
| Gemcitabine | NR18 | CR: 22% | Duration of CR: 10 mo |
| NR19 | CR: 11.5% | Duration of CR: 15 mo | |
| NR20 | ORR: 51% | DFI: 15-120 mo | |
| Pegylated liposomal doxorubicin | RA21 | ORR stage IA-IV: 88% | DFS: 13.3 mo |
| NR25 | ORR: 41% | DOR: 6 mo | |
| Low-dose methotrexate | RA22 | ORR T2 disease: 33% | TTF: 15 mo |
| RA23 | ORR T4 disease: 58% | TTF: 31 mo | |
| Pralatrexate | NR24 | ORR transformed disease: 25% | PFS: 1.7 mo |
| Therapy . | Study type . | Efficacy . | Durability . |
|---|---|---|---|
| EPOCH | NR14 | ORR stage IIB-IV: 80% | PFS: 8 mo |
| CHOP-based | NR15 | ORR stage IIB: 66% | |
| Fludarabine plus α-interferon | NR16 | ORR stage IIA-IVA: 58% | PFS: 5.9 mo |
| ORR stage IVB: 40% | |||
| Fludarabine plus cyclophosphamide | NR17 | ORR stage IIB-III: 55% | DOR: 10 mo |
| Gemcitabine | NR18 | CR: 22% | Duration of CR: 10 mo |
| NR19 | CR: 11.5% | Duration of CR: 15 mo | |
| NR20 | ORR: 51% | DFI: 15-120 mo | |
| Pegylated liposomal doxorubicin | RA21 | ORR stage IA-IV: 88% | DFS: 13.3 mo |
| NR25 | ORR: 41% | DOR: 6 mo | |
| Low-dose methotrexate | RA22 | ORR T2 disease: 33% | TTF: 15 mo |
| RA23 | ORR T4 disease: 58% | TTF: 31 mo | |
| Pralatrexate | NR24 | ORR transformed disease: 25% | PFS: 1.7 mo |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CR, complete response; DFI, disease-free interval; DFS, disease-free survival; EPOCH, etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisolone; NR, nonrandomized; RA, retrospective analysis; TTF, time-to-treatment failure.